Management Of Feline Infectious Peritonitis

Management Of Feline Infectious Peritonitis

Shruti Shaurya¹

¹M.V.Sc. Scholar, Division of Medicine, ICAR-Indian Veterinary Research Institute, Izatnagar, U.P., 243122

Abstract

Feline Infectious Peritonitis (FIP) is a fatal disease in cats caused by certain strains of the feline coronavirus, presenting significant diagnostic and treatment challenges. Traditionally, supportive care like fluid therapy, anti-inflammatory drugs, and nutritional support offered limited success. Recent advancements, particularly with the nucleoside analog GS-441524, have revolutionized FIP treatment by inhibiting viral replication and improving survival rates. Adjunct therapies, including immune modulators and interferons, are under investigation to enhance outcomes further. Early diagnosis and intervention are crucial for treatment efficacy. Ongoing research into the genetic basis and vaccine development holds promise for more effective prevention and management strategies, improving prognosis and quality of life for affected cats.

 Keywords: Antiviral therapy, Coronavirus, Interferons

 Introduction

Feline Infectious Peritonitis (FIP) remains one of the most challenging diseases in feline medicine. Caused by a mutation of the relatively benign feline enteric coronavirus (FECV), FIP manifests in two forms: the effusive (wet) form and the non-effusive (dry) form, both leading to high mortality rates. The complexity of FIP arises from its pathogenesis, where the immune response plays a critical role in disease progression. Historically, FIP was deemed incurable, but recent advancements have revolutionized its management, offering new treatment avenues and improved prognosis.

Pathogenesis and Clinical Manifestations

FIP results from a mutation of the feline coronavirus (FCoV), which typically resides in the gastrointestinal tract of cats. Upon mutation, the virus gains the ability to replicate within macrophages, leading to widespread immune-mediated vasculitis and granuloma formation (Pedersen, 2009). Effusive FIP is characterized by fluid accumulation in body cavities, leading to symptoms like abdominal distension and respiratory distress. Non-effusive FIP manifests as granulomatous lesions in various organs, causing neurological signs, ocular abnormalities, and organ failure (Addie et al., 2009).

 Diagnostic Approaches

1. Clinical Signs and History: Observation of clinical signs and thorough history taking, including age (young cats are more susceptible), no history of vaccination, environment (multi-cat households) and previous FCoV exposure (Hartmann, 2005).

Fig. 1. Cat suffering from FIP a. Emaciated, dull; b. Icteric conjunctival mucous        membrane; c. Icteric gums

1. Laboratory Tests: Blood tests showing hyperglobulinemia, hypoalbuminemia, and lymphopenia. Elevated serum protein concentrations, particularly globulins, are common in FIP (Felten & Hartmann, 2019).

• Imaging: Ultrasound and radiography detect effusions and organ involvement, revealing fluid accumulations, organ enlargement, and thickened intestinal walls.

1. Fluid Analysis: The Rivalta test is used to analyze effusion fluid for high protein content and low cellularity, critical for diagnosing effusive FIP (Hartmann, 2005).
2. PCR Testing: Detection of FCoV RNA in effusion fluids or tissues via PCR identifies the presence of FCoV but does not distinguish between benign and virulent strains (Felten & Hartmann, 2019).
3. Histopathology: Confirmation through biopsy and histopathological examination of affected tissues, where pyogranulomatous inflammation indicates FIP (Pedersen, 2009).

Therapeutic Interventions

1. Antiviral Therapies

GS-441524: An adenosine nucleoside analog showing significant efficacy in treating both forms of FIP, with high survival rates and rapid clinical improvement (Pedersen et al., 2019).

GC376: A 3C-like protease inhibitor effective in some FIP cases, particularly effusive FIP, leading to clinical remission in some cats (Kim et al., 2016).

2. Immunomodulatory Therapies

Interferons: Recombinant feline interferon-omega used to modulate immune responses, although not curative, may manage symptoms and prolong life (Hartmann, 2005).

Corticosteroids: Reduce inflammation and immune-mediated damage but are controversial due to potential immunosuppression. Prednisolone is sometimes used to alleviate symptoms (Pedersen, 2009).

3. Supportive Care

Nutritional Support: Ensuring adequate nutrition through palatable, high-quality diets or assisted feeding if necessary (Addie et al., 2009).

Fluid Therapy: Managing dehydration and maintaining electrolyte balance with intravenous or subcutaneous fluids (Hartmann, 2005).

Pain Management: Administering analgesics to manage pain and discomfort (Felten & Hartmann, 2019).

4. Antibiotics: Preventing secondary bacterial infections due to immunosuppression (Addie et al., 2009).
5. Emerging Therapies and Future Directions

CRISPR/Cas9: Gene-editing technology holds potential for targeting and disrupting the viral genome within infected cells (Kim et al., 2016).

Monoclonal Antibodies: Development of antibodies targeting specific viral proteins or immune modulators could offer a targeted approach.

Vaccine Development: Efforts to develop effective vaccines against FCoV to prevent FIP continue, although challenges persist (Pedersen, 2009).

Conclusion

The management of FIP has evolved significantly with advancements in diagnostic techniques and therapeutic options. While FIP remains a fatal disease, antiviral drugs such as GS-441524 and immunomodulatory therapies have provided a lifeline for affected cats. Continued research and clinical trials are essential to further improve treatment outcomes and potentially find a cure. Veterinarians must stay informed about the latest developments to offer the best possible care for cats with FIP.

 References

Addie, D. D., Toth, S., Murray, G. D., & Jarrett, O. (2009). The risk of feline infectious peritonitis in cats. Journal of Feline Medicine and Surgery, 11(9), 705-707.

Felten, S., & Hartmann, K. (2019). Diagnosis of feline infectious peritonitis: A review of the current literature. Viruses, 11(11), 1068.

Hartmann, K. (2005). Feline infectious peritonitis. Veterinary Clinics of North America: Small Animal Practice, 35(1), 39-79.

Kim, Y., Liu, H., Galasiti Kankanamalage, A. C., Weerasekara, S., Hua, D. H., Groutas, W. C., Chang, K. O., & Pedersen, N. C. (2016). Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathogens, 12(3), e1005531.

Pedersen, N. C. (2009). A review of feline infectious peritonitis virus infection: 1963-2008. Journal of Feline Medicine and Surgery, 11(4), 225-258.

Pedersen, N. C., Perron, M., Bannasch, M., Montgomery, E., Murakami, E., Liepnieks, M., & Liu, H. (2019). Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery, 21(4), 271-281.

Please follow and like us: